>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance:

  • HCSG +28.7%, SNAP +19.3%, STM +7.6%, CMG +7.4%, NDAQ +7.4%, TER +6.7%, USNA +6.2%, ERIC +5.1%, TMO +4.5%, DAL +3.5%, NAVI +3.3%, SLGN +2.9%, CETV +2.6%, TXN +2%, MANH +1.9%, LYFT +1.7% (withdraws FY20 rev/EBITDA guidance), NEE +1.5%, DGX +1.1%, KMB +1.1%, UCBI +1%, T +0.7%, TDY +0.7%

Other news:

  • IMUX +60.2% (its lead asset, IMU-838, has successfully demonstrated preclinical activity against COVID-19)
  • BNTX +34.9% (BioNTech and Pfizer announce regulatory approval from German authority to commence first clinical trial of COVID-19 vaccine candidates)
  • DKL +25.3% (this high yield stock reiterates expectation to raise distribution by 5% in 2020; also increases distribution slightly today), ANH +12.1% (reduces quarterly dividend)
  • MNK +8.2% (announces FDA acceptance for review of the co's NDA for terlipressin)
  • EXPE +6.6% (WSJ report that co is in advanced talks to sell a stake to private-equity firms)
  • BG +5.8% (to sell 35 U.S. grain elevators)
  • GME +5.2% (provides COVID update, reports comps)
  • QTNT +5% (reports positive performance data for its SARS-CoV-2 antibody test)
  • PFE +3.7% (BioNTech and Pfizer announce regulatory approval from German authority to commence first clinical trial of COVID-19 vaccine candidates)
  • USFD +3.4% (awarded $480 mln Defense Logistics Agency contract)
  • LH +3% (to expand serological testing for SARS-CoV-2 to more hospitals and healthcare organizations)
  • DCP +2.7% (reduces quarterly distribution)
  • BA +1.9% (announces organization changes)
  • IGT +1.8% (expands partnership with Virginia lottery)
  • GILD +1.7% (announces immunotherapy research collaboration)
  • FCAU +1.2% (announces drawdown of €6.25 bln revolving credit facility)
  • MYOV +1.1% (SPIRIT 2 met its co-primary efficacy endpoints and six key secondary endpoints)
  • BRT +1% (provides business update)

Analyst comments:

  • STAY +5% (upgraded to Buy from Hold at Jefferies)
  • CERN +2.3% (upgraded to Buy from Hold at Jefferies)
  • JNJ +1.8% (upgraded to Buy from Neutral at BofA/Merrill)